What is your treatment of choice in ALK-positive lung adenocarcinomas that have progressed on alectinib with resistance mutations that are not G1202R?
2 Answers
Mednet Member
Medical Oncology · University of Colorado Cancer Center
Lorlatinib has high response rates with any resistance mechanism.
Mednet Member
Medical Oncology · Boston Med Center
Data regarding use of lorlatinib after 1st or 2nd generation ALK-TKI failure comes from a phase II trial that enrolled multiple cohorts based on number/type of treatments received (i.e., 1st or 2nd gen. ALK-TKI with or without chemotherapy) (Shaw et al., PMID 30892989).
In this study, patients who ha...